Artificial intelligence is still struggling to crack the most complex problem in pharma R&D: reliably designing new molecules that become breakthrough medicines. But drugmakers say AI is already paying off in the “unsexy” middle of development. This is where time and money are often lost to paperwork, vendor hand-offs, and slow trial start-up. At the JPMorgan Healthcare Conference in January…